共 150 条
[1]
Parkin DM(2005)Global cancer statistics, 2002 CA Cancer J Clin 55 74-108
[2]
Bray F(2001)The status and trend of breast cancer incidence in Shanghai J Surg Concepts Pract 6 219-221
[3]
Ferlay J(1991)Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer Cancer Res 51 556-67
[4]
Zheng Y(1993)Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group J Clin Oncol 11 1936-42
[5]
Li DL(1993)Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease Cancer Res 53 4960-70
[6]
Xiang YM(1997)HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas J Clin Oncol 15 2894-904
[7]
Li XJ(1999)The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy Semin Cancer Biol 9 125-38
[8]
Paterson MC(2008)Her2-positive breast cancer: herceptin and beyond Eur J Cancer 44 2806-12
[9]
Dietrich KD(2000)Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples Am J Pathol 157 1467-72
[10]
Danyluk J(2006)HER-2 gene amplification by chromogenic in situ hybridisation (CISH) compared with fluorescence in situ hybridisation (FISH) in breast cancer-A study of two hundred cases Breast 15 519-27